Acorda Therapeutics Inc (ACOR) Major Shareholder Scopia Capital Management Lp Sells 225,000 Shares

Acorda Therapeutics Inc (NASDAQ:ACOR) major shareholder Scopia Capital Management Lp sold 225,000 shares of the firm’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $20.51, for a total value of $4,614,750.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Scopia Capital Management Lp also recently made the following trade(s):

  • On Thursday, November 29th, Scopia Capital Management Lp sold 50,000 shares of Acorda Therapeutics stock. The stock was sold at an average price of $20.20, for a total value of $1,010,000.00.
  • On Thursday, October 11th, Scopia Capital Management Lp sold 143,576 shares of Acorda Therapeutics stock. The stock was sold at an average price of $16.98, for a total value of $2,437,920.48.
  • On Tuesday, October 9th, Scopia Capital Management Lp sold 153,858 shares of Acorda Therapeutics stock. The stock was sold at an average price of $17.28, for a total value of $2,658,666.24.
  • On Tuesday, October 2nd, Scopia Capital Management Lp sold 32,649 shares of Acorda Therapeutics stock. The stock was sold at an average price of $18.89, for a total value of $616,739.61.
  • On Thursday, October 4th, Scopia Capital Management Lp sold 126,464 shares of Acorda Therapeutics stock. The stock was sold at an average price of $19.15, for a total value of $2,421,785.60.
  • On Thursday, September 6th, Scopia Capital Management Lp sold 13,829 shares of Acorda Therapeutics stock. The stock was sold at an average price of $27.82, for a total value of $384,722.78.
  • On Tuesday, September 4th, Scopia Capital Management Lp sold 200 shares of Acorda Therapeutics stock. The stock was sold at an average price of $29.00, for a total value of $5,800.00.

Shares of ACOR stock opened at $20.78 on Tuesday. The company has a market capitalization of $971.62 million, a PE ratio of 19.98 and a beta of 1.45. Acorda Therapeutics Inc has a fifty-two week low of $15.60 and a fifty-two week high of $36.35. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.95 and a current ratio of 4.03.

Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings data on Wednesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.15. The firm had revenue of $142.80 million for the quarter, compared to analyst estimates of $82.74 million. Acorda Therapeutics had a positive return on equity of 13.72% and a negative net margin of 24.88%. The business’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same period last year, the company earned $0.43 EPS. Research analysts forecast that Acorda Therapeutics Inc will post 0.08 earnings per share for the current year.

Several research firms recently issued reports on ACOR. Cantor Fitzgerald restated a “hold” rating and set a $32.00 price target on shares of Acorda Therapeutics in a research report on Monday, September 10th. BidaskClub upgraded Acorda Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 7th. Oppenheimer set a $18.00 price target on Acorda Therapeutics and gave the stock a “hold” rating in a research report on Sunday, September 23rd. Stifel Nicolaus reduced their price target on Acorda Therapeutics from $25.00 to $19.00 and set a “hold” rating on the stock in a research report on Friday, October 5th. Finally, HC Wainwright set a $28.00 price target on Acorda Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, October 24th. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $26.56.

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Acorda Therapeutics by 11.3% in the 3rd quarter. Vanguard Group Inc. now owns 5,384,536 shares of the biopharmaceutical company’s stock worth $105,806,000 after buying an additional 545,689 shares during the last quarter. TIAA CREF Investment Management LLC grew its position in shares of Acorda Therapeutics by 29.1% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 222,067 shares of the biopharmaceutical company’s stock worth $4,364,000 after buying an additional 50,083 shares during the last quarter. Teachers Advisors LLC grew its position in shares of Acorda Therapeutics by 71.7% in the 3rd quarter. Teachers Advisors LLC now owns 157,178 shares of the biopharmaceutical company’s stock worth $3,089,000 after buying an additional 65,634 shares during the last quarter. AQR Capital Management LLC grew its position in shares of Acorda Therapeutics by 436.3% in the 3rd quarter. AQR Capital Management LLC now owns 121,471 shares of the biopharmaceutical company’s stock worth $2,386,000 after buying an additional 98,822 shares during the last quarter. Finally, MetLife Investment Advisors LLC grew its position in shares of Acorda Therapeutics by 55.9% in the 3rd quarter. MetLife Investment Advisors LLC now owns 31,894 shares of the biopharmaceutical company’s stock worth $627,000 after buying an additional 11,439 shares during the last quarter.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.com-unik.info/2018/12/04/acorda-therapeutics-inc-acor-major-shareholder-scopia-capital-management-lp-sells-225000-shares.html.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.

Featured Story: Coverage Ratio

Insider Buying and Selling by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit